Transglottic acinic cell carcinoma. Case report and literature review.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Raad Issam I, Hachem Ray, Masayuki Nigo, Datoguia Tarcila, Dagher Hiba, Jiang Ying, Subbiah Vivek, Siddiqui Bilal, Bayle Arnaud, Somer Robert, Fernández Cruz Ana, Gorak Edward, Bhinder Arvinder, Mori Nobuyoshi, Hamerschlak Nelson, Shelanski Samuel, Dragovich Tomislav, Vong Kiat Yee Elise, Fakhreddine Suha, Pierre Abi Hanna, Chemaly Roy F, Mulanovich Victor, Adachi Javier, Borjan Jovan, Khawaja Fareed, Granwehr Bruno, John Teny, Yepez Eduardo Yepez, Torres Harrys A, Ammakkanavar Natraj Reddy, Yibirin Marcel, Reyes-Gibby Cielito C, Pande Mala, Ali Noman, Rojo Raniv Dawey, Ali Shahnoor M, Deeba Rita E, Chaftari Patrick, Matsuo Takahiro, Ishikawa Kazuhiro, Hasegawa Ryo, Aguado-Noya Ramón, García Alvaro Garcia, Puchol Cristina Traseira, Lee Dong Gun, Slavin Monica, Teh Benjamin, Arias Cesar A, Data-Driven Determinants for COVID-19 Oncology Discovery Effort (D3CODE) Team, Kontoyiannis Dimitrios P, Malek Alexandre E, Chaftari Anne-Marie
Аннотация
METHODS: We retrospectively collected de-identified data on a cohort of patients with and without cancer diagnosed with COVID-19 between January and November 2020 from 16 international centers.
RESULTS: We analyzed 3966 COVID-19 confirmed patients, 1115 with cancer and 2851 without cancer patients. Patients with cancer were more likely to be pancytopenic and have a smoking history, pulmonary disorders, hypertension, diabetes mellitus, and corticosteroid use in the preceding 2 wk (p≤0.01). In addition, they were more likely to present with higher inflammatory biomarkers (D-dimer, ferritin, and procalcitonin) but were less likely to present with clinical symptoms (p≤0.01). By country-adjusted multivariable logistic regression analyses, cancer was not found to be an independent risk factor for 30 day mortality (p=0.18), whereas lymphopenia was independently associated with increased mortality in all patients and in patients with cancer. Older age (≥65y) was the strongest predictor of 30 day mortality in all patients (OR = 4.47, p<0.0001). Remdesivir was the only therapeutic agent independently associated with decreased 30 day mortality (OR = 0.64, p=0.036). Among patients on low-flow oxygen at admission, patients who received remdesivir had a lower 30 day mortality rate than those who did not (5.9 vs 17.6%; p=0.03).
CONCLUSIONS: Increased 30 day all-cause mortality from COVID-19 was not independently associated with cancer but was independently associated with lymphopenia often observed in hematolgic malignancy. Remdesivir, particularly in patients with cancer receiving low-flow oxygen, can reduce 30 day all-cause mortality.
FUNDING: National Cancer Institute and National Institutes of Health.